Abstract
IntroductionIndividuals with depression who do not respond to two or more courses of serotonergic antidepressants tend to have greater deficits in reward processing and greater internalizing symptoms, yet there is no validated self-report method to determine the likelihood of treatment resistance based on these symptom dimensions.MethodsThis online case-control study leverages machine learning techniques to identify differences in self-reported anhedonia and internalizing symptom profiles of antidepressant non-responders compared to responders and healthy controls, as an initial proof-of-concept for relating these indicators to medication responsiveness. Random forest classifiers were used to identify a subset from a set of 24 reward predictors that distinguished among serotonergic medication resistant, non-resistant, and non-depressed individuals recruited online (N = 393). Feature selection was implemented to refine model prediction and improve interpretability.ResultsAccuracies for full predictor models ranged from .54 to .71, while feature selected models retained 3-5 predictors and generated accuracies of .42 to .70. Several models performed significantly above chance. Sensitivity for non-responders was greatest after feature selection when compared to only responders, reaching .82 with 3 predictors. The predictors retained from feature selection were then explored using factor analysis at the item level and cluster analysis of the full data to determine empirically driven data structures.DiscussionNon-responders displayed 3 distinct symptom profiles along internalizing dimensions of anxiety, anhedonia, motivation, and cognitive function. Results should be replicated in a prospective cohort sample for predictive validity; however, this study demonstrates validity for using a limited anhedonia and internalizing self-report instrument for distinguishing between antidepressant resistant and responsive depression profiles.
Reference119 articles.
1. Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults;Ettman;Lancet Reg Health – Am,2022
2. Diagnosis and definition of treatment-resistant depression;Fava;Biol Psychiatry,2003
3. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression;Gaynes;Psychiatr Serv,2009
4. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment–resistant depression;McMakin;J Am Acad Child Adolesc Psychiatry,2012
5. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure;Nutt;J Psychopharmacol (Oxf),2007